Healthcare
Seres Therapeutics, Inc.(MCRB)
Live Price
Offline$6.61
+2.32% today
1Y Change
-25.87%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $70.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +103.4%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Seres Therapeutics, Inc. (MCRB) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $6.61 and down 25.9% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +103.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +103.4%, free cash flow +100.6% with operating margin -11910.1% and ROIC -72.7%. Valuation already assumes a fairly strong business story at P/E 11.8 and price/sales 92.5. Stock Foundry combines MCRB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-11910.1% vs +19.4% peer median
P/E
Below sector median
11.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +103.4%, while operating margin sits near -11910.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -3.5% | -3.0% | -14.4% |
2026 Mar 12, 2026 | +20.9% | -4.6% | +0.3% | -8.1% |
2025 Nov 5, 2025 | +1780.0% | +9.1% | +26.1% | +40.9% |
Benchmark Edge
MCRB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MCRB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MCRB Max Drawdown
-80.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MCRB and SPY.
Company Overview
Seres Therapeutics, Inc.
NASDAQ Global Select
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Richard N. Kender
- IPO Date
- Jun 26, 2015
- Employees
- 103
- Street Address
- 200 Sidney Street
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 945 9626
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 11.8
- EV/EBITDA
- 15.8
- Price/Sales
- 92.5
- Price/Book
- 1.5
Growth
- Revenue
- 0.0%
- EPS
- +103.4%
- Free Cash Flow
- +100.6%
Profitability
- Gross Margin
- -423.8%
- Operating Margin
- -11910.1%
- Net Margin
- 721.9%
- ROE
- 13.3%
- ROIC
- -72.7%
Balance Sheet
- Debt/Equity
- 1.88
- Current Ratio
- 2.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.